NCT05497453 - A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2022

Primary Completion Date

November 21, 2024

Study Completion Date

November 21, 2024

Conditions

Hepatocellular CarcinomaSolid TumorHepatocellular Carcinoma Non-resectableHepatocellular Carcinoma RecurrentHepatocellular CancerLiver CancerLiver, Cancer Of, Non-Resectable

Interventions

DRUG

OTX-2002

OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.

DRUG

Tyrosine kinase inhibitor One

Tyrosine Kinase Inhibitor

DRUG

Tyrosine kinase inhibitor Two

tyrosine kinase inhibitor

DRUG

Checkpoint Inhibitor, Immune

monoclonal antibody that binds to PD-1 or PD-L1

Trial Locations (15)

32610

University of Florida Health Cancer Center, Gainesville

60637

University of Chicago, Chicago

70121

Ochsner Clinic Foundation, New Orleans

73104

Stephenson Cancer Center at Oklahoma University, Oklahoma City

91010

City of Hope, Duarte

98109

Fred Hutch / University of Washington, Seattle

Unknown

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

National Cancer Center Singapore, Singapore

National University Hospital, Singapore

Asan Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei